Navigation Links
Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
Date:4/29/2009

Company's work could help farmers protect against billions in pest losses annually

St. Louis, MO (PRWEB) April 29, 2009 -- In the past year, St. Louis biotech firm Divergence, Inc., has received more than $1.2 million in research grants, including a $500,000 grant just awarded from the National Science Foundation (NSF) to further the company's work on biotech traits for lesion nematode control in crops such as corn. The Phase II grant, "Control of Lesion Nematodes by RNA Interference," is part of NSF's Small Business Innovation Research (SBIR) program.

Nematodes are the largest unsolved pest problem in agriculture, limiting the yield of crops worldwide and causing billions of dollars in crop damage annually. Lesion nematodes are prevalent in the Corn Belt and appear to be increasing with changing agronomic practices. Divergence, a world leader in developing products for control of parasites in agriculture and medicine, has discovered nematicidal chemistry working through a novel mode of action and is also working on biotechnology-derived crops with built-in pest resistance.

The company's Phase I research demonstrated that RNA interference (RNAi) can substantially reduce lesion nematode reproduction resulting in a larger, healthier root system for a plant. The Phase II grant will allow Divergence to expand greenhouse testing in crops including corn. RNAi is a fundamental mechanism of gene regulation triggered by double-stranded RNA. Divergence was an early industrial adopter of RNAi, working with the research platform since the company's inception in 1999. Dr. Craig Mello, a member of Divergence's Scientific Advisory Board since 2000, was the co-recipient of the 2006 Nobel Prize in Physiology or Medicine for the discovery of RNAi.

"Our proje
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Divergence Raises $11.8 Million in Series C Financing
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Sunesis Pharmaceuticals Receives NASDAQ Notification
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. Cambrex Receives Notice Regarding NYSE Listing
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Capital ... solve complex business problems, is pleased to announce their ranking as one of the ... ranking of the fastest-growing private companies across the nation. , “It is truly an ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... Aug. 27, 2015 In response to ... UPS and The US Postal Service to no ... as ,select agents, by the CDC, Marken reaffirmed ... these sensitive shipments. Marken uses its ... trained and certified personnel to ensure the safe ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... Biodiesel Standards, VANCOUVER, British Columbia, June 20 ... night,s final vote by the ASTM,International D02 Main ... for biodiesel blends. After more than five years ... fuel experts in the,blended fuel balloting process, ASTM ...
... 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... Drug Administration (FDA) review, the Company is ... intravenous administration of REOLYSIN(R) in,combination with paclitaxel ... neck cancers. The Principal Investigator is Dr. ...
... GlaxoSmithKline (NYSE:,GSK) today announced that the U.S. ... in combination with tamsulosin for the,treatment of symptomatic ... men over 50 years old. The new indication ... medicines treats the symptoms of,enlarged prostate more effectively ...
Cached Biology Technology:Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 2Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 2FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 4
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... pioneering study of wild chimpanzees has found that these ... previous studies of captive individuals which had postulated that ... years of age. Together with recent data from ... week in the journal Current Biology -- suggests that ...
... from the University of Pennsylvania and Johns Hopkins University ... commonly activated proteins in cancer is so dangerous. ... protein can stop the production of at least 13 ... which genes are turned on and off. Furthermore, in ...
... people planning their day. Now with the help of NASA ... predictions of air quality, a feat that is becoming reality ... that an operational system of routine, global forecasts of air ... only a few years away. Such a system could prove ...
Cached Biology News:Wild chimpanzees appear not to regularly experience menopause 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2Air quality forecasts see future in space 2Air quality forecasts see future in space 3
... by BioLegend, the Quansys Biosciences Q-Plex Array ... of cytokines/chemokines for human, mouse, and rat ... a fully quantitative ELISA-based test where 4 ... each well of a 96-well plate in ...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: